Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

Executive Summary

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.

You may also be interested in...



First-Ever Point-Of-Care COVID-19 Serology Test Granted EUA By FDA

The US agency on 23 September granted emergency use authorization for the Assure COVID-19 IgG/IgM Rapid Test Device to be used in point-of-care settings like doctor’s offices, hospitals, urgent care centers and emergency rooms. The test requires a fingerstick to draw blood.

Government Report Outlines Costs, Savings Of Major Regs

The US HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.

US FDA Panel To Take Up Lutonix DCB Catheter For Lower-Leg Use Next Month

If approved, the device will be the first drug-coated balloon indicated specifically for use in arteries below the knee.

Topics

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel